Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 06/12/19 at 12:05pm

Corruption and bribery feature heavily in the news this week. A recently exposed 1997 email chain shows Dr Richard Sackler, member of the billionaire founding family of Purdue Pharma, knew about the potential abuse of opioids by its clients. In India, a recent report by the Support for Advocacy and Training to Health Initiatives (Sathi) revealed the widespread use of bribes by pharmaceutical companies in India, and how they take advantage of the lax government penalties against such actions.

In drug research and development news, in China a drug for male birth control may hold promise for treating lung cancer patients when treatments like immunotherapy do not work. In the US, Johnson & Johnson has secured approval from the FDA for its Tecnis Toris II 1-Piece Intraocular Lens (IOL).

10. Exclusive interview: Samsung Bioepis' Sang-Jin Pak on the rise of biosimilars

Following on from our focus on biosimilars in our feature last week, you can read Nikhil Patel's interview with Sang-Jin Pak, Senior Vice President & Head of Commercial at Samsung Bioepis, where he discusses the increasing prevalence of biosimilar medications and where the company stands within this.

9. Male birth control drug may hold promise for treating lung cancer, Chinese study finds

A drug for male birth control may hold promise for treating lung cancer patients when treatments like immunotherapy do not work.

8. FDA approves Johnson & Johnson cataract treatment

Johnson & Johnson has secured approval from the FDA for its Tecnis Toris II 1-Piece Intraocular Lens (IOL).

7. Purdue Pharma’s Richard Sackler ignored OxyContin addiction concerns, new emails show

A recently exposed 1997 email chain shows Dr Richard Sackler, member of the billionaire founding family of Purdue Pharma, knew about the potential abuse of opioids by its clients.

6. Roche's Tecentriq combo scores FDA approval in non-small cell lung cancer

Roche’s immunotherapy Tecentriq (atelizumab) has chalked up another approval from the FDA, this time in combination with the chemotherapy Abraxane (paclitaxel protein-bound; nab-paclitaxel and carboplatin) for the first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adult patients whose tumours display no EGFR or ALK genomic aberrations.

5. Allergan's ubrogepant doses smash primary endpoints in acute treatment of migraine

New Phase 3 data has been released showing that both 50mg and 100mg doses of Allergan’s ubrogepant met their primary endpoints in the acute treatment of migraine.

4. Roche's satralizumab shows promise at Phase 3 in neuromyelitis optica spectrum disorder

Roche has presented new data on its interleukin-6 (IL-6) inhibitor satralizumab in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a condition characterised by relapses which can lead to cumulative and permanent neurological damage and disability in affected patients.

3. NICE authorises Lynparza for NHS use in all BRCA-mutated ovarian cancer cases

NICE has given its recommendation for the routine use on the NHS in England and Wales of AstraZeneca and MSD’s Lynparza (olaparib) for the maintenance treatment of relapsed, advanced, BRCA+ ovarian cancer, it has been announced, making the drug available to all BRCA-mutated patients.

2. Study shows widespread bribery in Indian pharmaceutical industry

A recent report by the Support for Advocacy and Training to Health Initiatives (Sathi) revealed the widespread use of bribes by pharmaceutical companies in India, and how they take advantage of the lax government penalties against such actions.

1. The coming age of biosimilars

With more and more biosimilars securing approval and the sheer potential value they have to offer for healthcare systems around the world, Nikhil Patel takes a look at the current market landscape and how things could be shifting for the better.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches